Saladax Biomedical, Inc. Enters Agreement with Kaan Medikal for Distribution of My5-FU in Turkey
BETHLEHEM, Pa., Aug. 8, 2011 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Kaan Medikal will serve as the exclusive distributor of Saladax's My5-FU diagnostic test throughout the Turkish market.
My5-FU measures levels of 5-flourouracil (5-FU), a widely used chemotherapy drug used in conjunction with other drugs in first-line therapy for colorectal cancer and other solid tumors. The assay technology enables oncologists to determine the optimal dose of 5-FU for each individual patient, thereby increasing the effectiveness of the drug and lessening the risk of severe toxicity and side effects. My5-FU is the first of Saladax's innovative dose management tests commercially available.
"Kaan Medikal is an ideal partner for Saladax as we continue to expand the distribution and marketing of My5-FU in the European Union and other significant markets," said Adrienne Choma, Esq., vice president, marketing and sales of Saladax. "Interest in Turkey for My5-FU is strong, and we expect that Kaan Medikal's market leadership in diagnostic testing and excellent reputation for quality will enable significant opportunities for growth, which will translate into improved care for patients undergoing chemotherapy treatment for colorectal and other solid tumor cancers."
Fatih Ordu, general manager of Kaan Medikal, stated, "We are delighted to be working with Saladax to market My5-FU in Turkey. We're confident that Saladax's innovative diagnostic test will allow physicians in our country to better monitor and provide more accurate treatment to their patients."
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic assays to achieve the promise of personalized medicine through dose management and companion di